PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2016.0672017492350-357Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access ProgramMyoung Kyun Son, Min-Hee Ryu, Joon Oh Park, Seock-Ah Im, Tae-Yong Kim, Su Jin Lee, Baek-Yeol Ryoo, Sook Ryun Park, Yoon-Koo Kanghttp://www.e-crt.org/journal/view.php?doi=10.4143/crt.2016.067, http://www.e-crt.org/upload/pdf/crt-2016-067.pdf, http://www.e-crt.org/upload/pdf/crt-2016-067.pdf
BioDrugs10.1007/s40259-013-0061-22013275525-531Regorafenib: A Guide to Its Use in Advanced Gastrointestinal Stromal Tumor (GIST) After Failure of Imatinib and SunitinibKatherine A. Lyseng-Williamsonhttp://link.springer.com/content/pdf/10.1007/s40259-013-0061-2.pdf, http://link.springer.com/article/10.1007/s40259-013-0061-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40259-013-0061-2
Yearbook of Oncology10.1016/s1040-1741(08)79009-220082008303-305Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialP.J. Loehrerhttps://api.elsevier.com/content/article/PII:S1040174108790092?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1040174108790092?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdz283.035201930v698Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trialZ. Cai, B. Zhang, Y. Yin, D. Caohttps://api.elsevier.com/content/article/PII:S0923753419603248?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419603248?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz283.035/30082280/mdz283.035.pdf
Gastric Cancer10.1007/s10120-014-0391-x2014183627-634Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placeboChris D. Poole, Mark P. Connolly, Jane Chang, Craig J. Curriehttp://link.springer.com/content/pdf/10.1007/s10120-014-0391-x.pdf, http://link.springer.com/article/10.1007/s10120-014-0391-x/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10120-014-0391-x
Nature Clinical Practice Oncology10.1038/ncponc0814200746342-343Sunitinib—a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumorMaria Debiec-Rychterhttp://www.nature.com/articles/ncponc0814.pdf, http://www.nature.com/articles/ncponc0814, http://www.nature.com/articles/ncponc0814.pdf
Gastroenterology Research and Practice10.1155/2014/342986201420141-6Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and SunitinibAkira Sawaki, Tatsuo Kanda, Yoshito Komatsu, Toshirou Nishidahttp://downloads.hindawi.com/journals/grp/2014/342986.pdf, http://downloads.hindawi.com/journals/grp/2014/342986.xml, http://downloads.hindawi.com/journals/grp/2014/342986.pdf
Reactions Weekly10.1007/s40278-020-84611-9202018261164-164Imatinib/regorafenib/sunitinibhttp://link.springer.com/content/pdf/10.1007/s40278-020-84611-9.pdf, http://link.springer.com/article/10.1007/s40278-020-84611-9/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-020-84611-9.pdf
Annals of Oncology10.1093/annonc/mdy299.019201829viii583Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinibH. Cho, M.-H. Ryu, B.J. Kim, Y. Park, Y.-S. Na, J. Ma, M.Y. Beck, Y.-K. Kanghttps://api.elsevier.com/content/article/PII:S0923753419500850?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419500850?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy299.019/26137874/mdy299.019.pdf
The Oncologist10.1634/theoncologist.2019-003320192411Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and SunitinibJae‐Joon Kim, Min‐Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon‐Koo Kanghttps://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2019-0033, https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.2019-0033, https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2019-0033